Comparative Pharmacology
Head-to-head clinical analysis: VEETIDS 500 versus VERSAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VEETIDS 500 versus VERSAPEN.
VEETIDS '500' vs VERSAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VEETIDS '500' (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis. It has activity against both gram-positive and gram-negative bacteria.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
1 tablet (500 mg) orally twice daily for 7 days.
500 mg IV every 6 hours or 1 g IV every 8 hours for moderate infections; 2 g IV every 4 hours for severe infections.
None Documented
None Documented
4-6 hours (prolonged in renal impairment; requires dose adjustment if CrCl <30 mL/min)
0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in anuria. Requires dose adjustment in renal impairment.
Renal: 60-80% unchanged; biliary/fecal: 15-25% as metabolites
Renal: 60-70% unchanged via glomerular filtration and tubular secretion. Biliary: <10% excreted unchanged. Fecal: 20-30% as metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic